Laura P Stabile

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3268036/publications.pdf

Version: 2024-02-01

43	2,105	257450 24	289244 40
papers	citations	h-index	g-index

43	43	43	2804
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen. Cancer Research, 2002, 62, 2141-50.	0.9	362
2	HGF and c-Met Participate in Paracrine Tumorigenic Pathways in Head and Neck Squamous Cell Cancer. Clinical Cancer Research, 2009, 15, 3740-3750.	7.0	196
3	The Role of the Estrogen Pathway in the Tumor Microenvironment. International Journal of Molecular Sciences, 2018, 19, 611.	4.1	145
4	Combined Analysis of Estrogen Receptor Î²-1 and Progesterone Receptor Expression Identifies Lung Cancer Patients with Poor Outcome. Clinical Cancer Research, 2011, 17, 154-164.	7.0	139
5	Dual Blockade of EGFR and c-Met Abrogates Redundant Signaling and Proliferation in Head and Neck Carcinoma Cells. Clinical Cancer Research, 2011, 17, 4425-4438.	7.0	106
6	Estrogen receptor beta (ERÎ²) subtype-specific ligands increase transcription, p44/p42 mitogen activated protein kinase (MAPK) activation and growth in human non-small cell lung cancer cells. Journal of Steroid Biochemistry and Molecular Biology, 2009, 116, 102-109.	2.5	105
7	Estrogenic Steroid Hormones in Lung Cancer. Seminars in Oncology, 2014, 41, 5-16.	2.2	95
8	Estrogen receptor pathways in lung cancer. Current Oncology Reports, 2004, 6, 259-267.	4.0	93
9	c-Src Activation Mediates Erlotinib Resistance in Head and Neck Cancer by Stimulating c-Met. Clinical Cancer Research, 2013, 19, 380-392.	7.0	90
10	Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer. Lung Cancer, 2009, 64, 51-59.	2.0	82
11	Sex specific function of epithelial STAT3 signaling in pathogenesis of K-ras mutant lung cancer. Nature Communications, 2018, 9, 4589.	12.8	57
12	Prevention of tobacco carcinogen-induced lung cancer in female mice using antiestrogens. Carcinogenesis, 2012, 33, 2181-2189.	2.8	48
13	Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis, 2005, 27, 1547-1555.	2.8	43
14	MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance. Molecular Oncology, 2017, 11, 628-639.	4.6	43
15	Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Molecular Cancer Therapeutics, 2008, 7, 1913-1922.	4.1	37
16	Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced nonâ€“small cell lung cancer. Cancer, 2017, 123, 2936-2944.	4.1	36
17	Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer. Lung Cancer, 2018, 123, 91-98.	2.0	35
18	ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget, 2016, 7, 57714-57725.	1.8	35

#	Article	IF	Citations
19	Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers, 2010, 2, 2153-2170.	3.7	34
20	Lung Endothelial MicroRNA-1 Regulates Tumor Growth and Angiogenesis. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1443-1455.	5.6	31
21	Targeting the estrogen pathway for the treatment and prevention of lung cancer. Lung Cancer Management, 2014, 3, 43-52.	1.5	30
22	ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker. Journal of Cancer, 2018, 9, 2559-2570.	2.5	30
23	Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome. Neoplasia, 2015, 17, 817-825.	5.3	29
24	Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. Oncotarget, 2017, 8, 24063-24076.	1.8	26
25	Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 399-412.	1.1	25
26	Sex and gender differences in lung cancer. Journal of Gender-specific Medicine, 2003, 6, 37-48.	0.1	21
27	Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer. Cancers, 2020, 12, 1537.	3.7	19
28	Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist, 2022, 27, 839-848.	3.7	18
29	The endocrine disrupting alkylphenols and 4,4â€²-DDT interfere with estrogen conversion and clearance by mouse liver cytosol. Reproductive Biology, 2017, 17, 185-192.	1.9	17
30	Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration. Cancer Research, 2019, 79, 2962-2977.	0.9	16
31	Syngeneic tobacco carcinogenâ€“induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden. JCI Insight, 2021, 6, .	5.0	13
32	Interplay between estrogen and Stat3/NF-Î¹B-driven immunomodulation in lung cancer. Carcinogenesis, 2020, 41, 1529-1542.	2.8	9
33	Estrogen Receptor ÃŸ in Cancer: To ÃŸ(e) or not to ÃŸ(e)?. Endocrinology, 2021, 162, .	2.8	8
34	The estrogen pathway as a modulator of response to immunotherapy. Immunotherapy, 2019, 11, 1161-1176.	2.0	7
35	Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF. Journal of Thoracic Oncology, 2014, 9, 1285-1293.	1.1	6
36	A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab. Biomarker Research, 2019, 7, 14.	6.8	6

#	Article	IF	Citations
37	Targeting the ERÎ²/HER Oncogenic Network in KRAS Mutant Lung Cancer Modulates the Tumor Microenvironment and Is Synergistic with Sequential Immunotherapy. International Journal of Molecular Sciences, 2022, 23, 81.	4.1	6
38	Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates. Journal of Cancer, 2017, 8, 3916-3932.	2.5	3
39	Induction of Lung Tumors and Mutational Analysis in FVB/N Mice Treated with the Tobacco Carcinogen 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanone. Methods in Molecular Biology, 2020, 2102, 149-160.	0.9	3
40	When fat is favorable: the unexpected relationship between obesity and response to immunotherapy. Immunotherapy, 2020, 12, 1035-1039.	2.0	1
41	HGF Airway Over-expression Leads to Enhanced Pulmonary Vascularization without Induction of VEGF. Current Angiogenesis, 2012, 1, 52-63.	0.1	0
42	Hormone gene signature guides a novel therapeutic opportunity to improve sensitivity to HER family inhibition in lung cancer. Translational Lung Cancer Research, 2020, 9, 1599-1605.	2.8	0
43	Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2020, 38, TPS6594-TPS6594.	1.6	0